Synapse: Law for Life Sciences





Welcome to Synapse - connecting you with news and analysis on legal and commercial issues in the life sciences.

visit N-Site
visit the Taylor Wessing Patent Map
visit Global Data Hub

COVID-19 and life sciences M&A


While the commercial and transactional impact of COVID-19 is still being played out, our experts examine the already significant differences in how life sciences mergers and acquisitions are being carried out in this environment.


arrowView our previous articles

Topical Issues


Patent pools - an easy licensing option for COVID-19 drugs and SARS CoV 2 vaccines? - Anja Lunze and Jan Phillip Rektorschek explain how patent pools may provide an easy licensing option for COVID-19 drugs and SARS CoV 2 more


Privacy regulator guidance for life sciences and healthcare in light of COVID-19 - Thanos Rammos provides an update of the privacy regulator guidance in light of more


A Czech perspective on COVID-19 and healthcare law - Barbora Dubanská and Patrick Boháček provide an overview of the legal implications of COVID-19 in the Czech healthcare more


COVID-19 and public compulsory licensing of drugs in Europe - Our European experts explain how, in emergency situations, governments may be able to rely on compulsory licensing powers to ensure supplies of medicines and equipment to the more


NHS can procure drugs for use outside of their approved indications if it's cheaper, court says - Justyna Ostrowska explains the recent decision of the English Court of Appeal to allow a controversial drug cost-cutting policy for the more


Patents diary: April 2020 - The English Court of Appeal has clarified the level of detail needed in an Arrow declaration in the English more

Subscribe to Synapse

Receive our monthly newsletter keeping you updated on recent developments and events in the Life Sciences sector.
Register here